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Objective: Patients with head and neck cancer with Medicaid or no insurance present at a more advanced stage
and have lower survival. This study is one of the first to examine the relationship between specific insurance
types and overall survival for laryngeal squamous cell carcinoma patients.
Study design: Retrospective chart review.
Setting: Henry Ford Cancer Institute.
Subjects and methods: A retrospective database review was performed using the Henry Ford Virtual Data Ware
house Tumor Registry. Six hundred and fifty patients diagnosed with laryngeal squamous cell carcinoma were
identified. Insurance groups analyzed were fee for service, health maintenance organization, Henry Ford Medical
Group - a managed care type insurance, Medicare and Medicaid/uninsured. Cox proportional hazards and
Kaplan-Meier curves were generated to analyze overall survival and display survival differences respectively.
Results: The uninsured group had the lowest median survival time of 29.8 months (95% CI: 20.3–44.8) and the
highest HR of 1.85 (95% CI 1.16–2.93) as compared to the HMO group at p < 0.001. Patients with fee for service
insurance had longer overall survival compared to the other insurance types. Patients with fee for service in
surance also had a high proportion of patients with advanced stage disease, but a younger mean age. Henry Ford
Medical Group had a higher mean age and no statistically significant difference in survival when compared to fee
for service. (p = 0.999) After controlling for socioeconomic status, insurance type remains a significant predictor
of overall survival.
Conclusions: Fee for service had the highest overall survival of the different insurance types, but it was only
statistically significant when compared to the Medicaid/uninsured group.

1. Introduction
The incidence of laryngeal squamous cell carcinoma is estimated at
3.2 cases per 100,000 people with 3710 estimated deaths in 2018 [1]. A
key prognostic indicator in survival is early stage at presentation. The 5year survival for localized laryngeal cancer is 77.5% compared to 33.5%
in those who present with lymph node metastases [1]. Early stage dis
ease may be treated conservatively with radiation or organ preservation
surgery. At advanced stages, the gold standard treatment is either a total
laryngectomy or chemoradiation. Advance stage treatment, however,
confers greater morbidity, such as loss of voice and impaired swallow
ing. Additionally, a significant portion of those undergoing chemo
radiation present with persistent or recurrent disease, requiring salvage
laryngectomy [2]. Socioeconomic factors, such as income and insurance

status, play a key role in identifying populations that present with
advanced-stage cancers [3–11].
Previous studies have shown that patients with head and neck cancer
who are uninsured at diagnosis present at a later stage and with greater
tumor burden than those with private insurance [3,6]. These results
have been consistent in oral cavity, oropharyngeal, and laryngeal can
cers and can also be seen in other cancers, including breast, colorectal,
lung, and hematologic malignancies [6–10,12,13]. As expected from
presenting with advanced disease, patients with head and neck cancer
without insurance have worse overall survival compared to those with
private insurance [7,8]. Additionally, they have a higher mortality
compared to the insured, even after controlling for stage at presentation
[4]. Prior studies have also demonstrated that patients with Medicaid
and Medicare diagnosed with cancer often have worse overall survival
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compared to those with private insurance [4,9]. As such, insurance
status appears to have strong associations with cancer survival, even
after controlling for other factors such as race [12,13]. Indeed, research
in 2015 using the National Cancer Database examined the relative sur
vival of patients with Medicare, Medicaid, private, uninsured, and un
known insurance in regards to laryngeal squamous cell cancer [5]. This
study concluded that patients with Medicaid or without insurance had
decreased relative survival compared to those with private insurance
[5]. These findings have implications in regard to the state of health care
systems in the United States and providing greater access to health care.
To our knowledge, no study has previously compared overall sur
vival of patients with laryngeal cancer among Medicare, Medicaid, and
different private insurance types. The current study examines the effect
of various private insurance types (health maintenance organization
[HMO] managed care insurance, Fee for Service [FFS], and an HMO
specific to our institution, Henry Ford Medical Group Confined [HFMG
Confined]), in addition to Medicare, Medicaid, and no insurance on
laryngeal cancer survival. The study also examined the contributions of
markers of socioeconomic status (SES) in the various insurance pop
ulations and the interaction of these markers with overall survival.

3. Results
Six hundred fifty patients diagnosed with laryngeal squamous cell
carcinoma were identified in the tumor registry from 1990 to 2013. In
the overall sample, 78% of patients were male, with a mean age of 64
years (SD = 11.2). The overall mean of the median household income in
the patient’s zip code was $43,919.60 (SD = $22,822.30). The largest
proportion of patients had FFS type insurance (52.4%), followed by
HMO (16.2%), HFMG (14.9%), Uninsured (11.1%) and Medicaid
(5.4%).
Table 1A shows the hazard ratios between the different insurance
groups stratified by AJCC8 staging criteria for laryngeal squamous cell
carcinoma; this was further grouped into two broad categories as early
stage and late stage. There was no significant difference in survival
probability between the insurance groups for Stage 0/carcinoma in situ
(n = 75), Stage I (n = 195), and Stage II (n = 112) cancers (p = 0.118,
Table 1A
Survival by insurance type stratified by AJCC stage.

2. Methods
Henry Ford Health System’s Virtual Data Warehouse Tumor Registry
was used to identify patients with a diagnosis of laryngeal squamous cell
carcinoma from 1990 to 2013. Demographic information, including age,
sex, and race/ethnicity, were found within the database. Additionally,
disease-specific data such as diagnosis date, treatment dates, follow-up,
vital status, and date of death were included. The American Joint
Committee on Cancer staging criteria at diagnosis was also available in
the database. Socioeconomic markers were included using 2010 US
Census block data, which provided median household income, educa
tion level, and household status at the level of the patient’s census block
at time of diagnosis.
The different insurance types evaluated were FFS, HMO managed
care insurance, HFMG Confined, Medicare, and Medicaid/uninsured.
Medicaid and uninsured patients were grouped together as many pa
tients present as uninsured for their initial cancer diagnosis and treat
ment only to later apply for and be granted Medicaid insurance after
initiation of cancer care. Institutional review board approval from Henry
Ford Health System was obtained for the study.

AJCC stage (N)a

Insurance group (ref
grp = HMO)

HR

95% CI

Pvalue

Early (N
= 382)

FFS

6.60

0.118

HFMG

2.30

Medicaid

14.00

Uninsured

2.94

FFS

1.03

HFMG

0.90

Medicaid
Uninsured

N/A
2.79

FFS

1.41

HFMG

0.51

Medicaid
Uninsured

N/A
1.41

FFS

1.24

HFMG

0.94

Medicaid

3.78

Uninsured

4.86

FFS

2.95

HFMG
Medicaid
Uninsured

N/A
None
6.99

FFS

0.81

HFMG

1.10

Medicaid

0.52

Uninsured

1.40

FFS

1.15

HFMG

1.64

Medicaid

0.44

Uninsured

0.39

0.86,
50.73
0.26,
20.67
0.83,
237.51
0.27,
32.62
0.62,
1.72
0.47,
1.73
N/A
1.26,
6.19
0.66,
3.01
0.17,
1.51
N/A
0.50,
3.94
0.43,
3.55
0.26,
3.35
0.81,
17.71
1.36,
17.39
0.87,
10.05
N/A
None
1.88,
25.92
0.43,
1.54
0.48,
2.52
0.21,
1.31
0.40,
4.95
0.21,
6.33
0.21,
12.57
0.04,
5.34
0.03,
4.95

0 (N = 75)

I, IA, IB (N
= 195)

II (N =
112)

Late (N =
268)

III (N = 80)

2.1. Statistical analysis
The primary aim of this analysis was to compare overall survival
between insurance types. Insurance was grouped into 5 types: FFS,
HFMG Confined, HMO, Medicaid/uninsured, and Medicare. Continuous
data are described using means and standard deviations, while cate
gorical data are described using counts and percentages. Overall sur
vival time is calculated by taking the difference between diagnosis date
and date of death or date of last known contact in those known to be
deceased but without a verifiable date of death on record. Patients are
considered censored if they were alive at last known contact date or
were known to be alive without date of death. Overall survival distri
butions are compared between groups using a log-rank test, and median
survival times with 95% CIs are calculated using the life-test method.
Cox proportional hazards models are used to examine the effect of in
surance type on survival while controlling for other variables such as
stage and SES. Kaplan-Meier curves are produced to visualize survival
differences. Stage and site were compared between insurance groups
using Fisher’s exact tests due to small group sizes, while continuous
variables were compared between insurance groups using Wilcoxon
signed-rank tests due to non-normal distributions. Statistical signifi
cance is set at p < 0.05. All analyses are completed using SAS 9.4 (SAS
Institute Inc., Cary, NC).

IV (N = 50)

IVA (N =
124)

IVB/IVC
(N = 14)

a

No patients in the original 650 had Insurance Group = Other.
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0.073, and 0.220, respectively). There was a significant difference in
survival probability overall between the insurance groups for Stage III
(n = 80) and non-specific Stage IV (n = 50) cancers (p = 0.017 and p =
0.016, respectively); however, there was no statistical difference in HRs
for Stage IVA (n = 124) and IVB/IVC (n = 14) cancers (p = 0.491 and p
= 0.744, respectively). Table 1B shows the sample size for each insur
ance group stratified by AJCC8 staging.
Analysis of Stage 0 did not include enough data to provide a median
survival time as <50% of this cohort died. Stage I had the highest me
dian survival time of 120.6 months (95% CI: 102.1–150.9), followed by
Stage II at 91.3 months (95% CI: 64.4–114.7), Stage III at 69.0 months
(95% CI: 32.5–87.6), Stage IV at 40.3 months (95% CI: 18.6–58.8), Stage
IVA at 29.3 months (95% CI: 17.8–52.2), and Stage IVB/IVC at 4.8
months (95% CI: 1.5–11.0) (Table 2).
The most frequent treatment modality seen in the HMO group was
radiotherapy (RT) only at 56.8% (50/88), RT only for FSS at 49.6%
(137/276), surgery only for Medicaid at 34.3% (11/32), RT only for
HFMG at 51.3% (39/76), and RT only for uninsured at 72.9% (35/48)
(Table 3). The overall most frequent modality was RT only at 51.2%
(266/520), followed by surgery only at 18.0% (94/520), chemo
radiation (CRT) at 11.9% (62/520), surgery & adjuvant RT at 11.9%
(62/520), surgery and adjuvant CRT at 4.6% (24/520), salvage surgery
at 1.2% (6/520), and chemotherapy only at 1.2% (6/520) (Table 3).
Table 4A shows the effect of primary treatment and stage on survival
probability via a multivariable Cox proportional hazards model; how
ever it shows the proportional hazards assumption for a multivariable
model using primary treatment and stage as independent variables. Due
to this issue, the model was instead stratified by treatment as shown in
Table 4B. Table 4B shows the effect of stage on survival probability,
stratified by primary treatment. With this adjustment, the adjusted HR
was still the highest in the Stage IVB/IVC group as compared to the Stage
0 group with a HR of 21.51 (95% CI: 7.29–63.52) and p-value of <0.001.
Table 5 shows the number of patients in each AJCC stage and the
modality of treatments they received. For Stage 0 the most common
modality of treatment was surgery (50%; 17/34), RT only for Stage I
(72.6%; 119/164), RT only for Stage II (74.3%; 75/101), CRT for Stage
III (33.3%; 21/63), RT only for Stage IV (72.5%; 29/40), surgery &
adjuvant RT for Stage IVA (27.3%; 30/110), and RT only for Stage IVB/
IVC (50%; 4/8).
Table 6 shows a multivariable survival model of insurance type when
controlling for socioeconomic variables. There was a significant differ
ence in median survival and HRs between the insurance groups overall.
The uninsured group had the lowest median survival time of 29.8
months (95% CI: 20.3–44.8) and the highest HR of 1.85 (95% CI
1.16–2.93) as compared to the HMO group at p < 0.001. This is reflected
in the Kaplan-Meier survival curve as well (Fig. 1). There was also a
significant increased risk in death with every 1-year increase in age (HR:
1.06 (95% CI: 1.05–1.08), p < 0.001), being female (HR: 1.34 (95% CI:
1.01–1.76), p = 0.041) and with higher stage with Stage IVB/IVC being
the highest HR: 28.56 (95% CI: 12.81–63.7), p-value of <0.001
(Table 6). The SES markers of education, poverty status, housing status,
race and median household income did not significantly affect the risk of
death.

Table 2
Median survival time by AJCC stage.
AJCC

Median survival time (months)

0
I, IA, IB
II
III
IV
IVA
IVB/IVC

N/A
120.6
91.3
69.0
40.3
29.3
4.8

0
I, IA, IB
II
III
IV
IVA
IVB/IVC
Total

111.7, N/A
102.1, 150.9
64.4, 114.7
35.2, 87.6
18.6, 58.8
17.8, 52.2
1.5, 11.0

a

Survival probability in this cohort never surpassed 50% so the median sur
vival time and upper limit of the confidence interval are undefined.
Table 3
Insurance group by primary treatment.
Primary Tx

Insurance Group

Surgery only
RT only
Chemo RT
Surgery & adjuvant
RT
Surgery & adjuvant
chemo RT
Salvage surgery
Chemo only
Total

HMO

FFS

Medicaid

HFMG

Uninsured

Total

16
50
7
13

49
137
36
34

11
5
3
5

16
39
10
6

2
35
6
4

94
266
62
62

1

14

6

2

1

24

0
1
88

2
4
276

2
0
32

2
1
76

0
0
48

6
6
520

Table 4A
Effect of primary treatment and stage on survival probability, multivariable
model.
Variable

Response

Adj HR

Primary tx

Chemo RT
Chemo only
RT only
Salvage surgery
Surgery & adjuvant RT
Surgery & adjuvant chemo RT
Surgery only
0
I, IA, IB
II
III
IV
IVA
IVB/IVC

(ref)
1.50
1.06
2.11
0.90
0.66
0.69
(ref)
1.56
2.15
3.05
4.10
4.44
24.03

AJCC stage

95% CI
0.51,
0.68,
0.81,
0.55,
0.31,
0.42,

4.38
1.66
5.49
1.46
1.41
1.15

0.75,
1.01,
1.37,
1.86,
2.02,
8.45,

3.28
4.56
6.77
9.04
9.74
68.31

P-value
0.170

<0.001

Table 4B
Effect of stage on survival probability, stratified by primary treatment.
Variable

Response

Adj HR

95% CI

AJCC stage

0
I, IA, IB
II
III
IV
IVA
IVB/IVC

(ref)
1.53
2.11
3.16
3.92
4.44
21.51

0.73,
0.99,
1.41,
1.78,
2.02,
7.29,

Table 1B
Breakdown of AJCC stage by insurance group (counts).
AJCC

95% CI

a

3.22
4.49
7.05
8.64
9.77
63.51

P-value
<0.001

Insurance group
HMO

FFS

Medicaid

HFMG

Uninsured

Total

4. Discussion

12
43
17
8
5
18
2
105

32
101
65
45
22
69
7
341

4
4
3
4
0
18
2
35

18
35
15
12
1
14
2
97

9
12
12
11
22
5
1
72

75
195
112
80
50
124
14
650

Previous research has demonstrated that Medicaid or uninsured
patients with head and neck cancer present at more advanced stage and
have worse survival than their counterparts with private insurance [3].
This has been confirmed across many other types of cancers
[4,6–10,12,13]. The results of the current study further support these
findings and highlight that laryngeal cancer is no exception. Adding to
3
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insurance is likely due to access to and coordination of care, which is
integral to the managed care model. Even within patients presenting at
an advanced stage, the patients with FFS or HFMG insurance had the
highest median survival and 5-year survival probability among the in
surance groups studied. Of note, when stratified by stage of presenta
tion, the overall survival for Stage I and Stage IV was not statistically
different when comparing the FFS and HFMG groups to the Medicare
group. This may be due to the fact that Stage I laryngeal cancer has high
intrinsic cure rates, and thus, high overall survival; hence, differences
between the FFS, HFMG and Medicare groups may not be statistically
significant. Based on the current study, the same cannot be said for the
Medicaid/uninsured population. For advanced stage disease, Stage IV,
the overall cure rate is lowest, and thus, survival would be expected to
be the lowest as well. There are some studies demonstrating longer
cancer survival in patients with Medicare compared to those who were

Table 5
Primary treatment vs stage.
Primary Tx

AJCC Stage

Surgery only
RT only
Chemo RT
Surgery & adjuvant
RT
Surgery & adjuvant
chemo RT
Salvage surgery
Chemo only
Total

0

I, IA,
IB

17
15
0
2

26
119
0
16

0
0
0
34

II

III

IV

IVA

IVB/
IVC

Total

11
75
8
6

14
18
21
5

2
29
6
3

23
6
26
30

1
4
1
0

94
266
62
62

0

0

2

0

21

1

24

1
2
164

0
1
101

3
0
63

0
0
40

2
2
110

0
1
8

6
6
520

the current literature, this study demonstrates that patients with
managed care insurance presented at earlier stage compared to the other
insurance types. Early symptoms of laryngeal cancer often include
hoarse voice, odynophagia and dysphagia; there is speculation that
patients with Medicaid or those who are uninsured fear the financial
demands of pursuing medical treatment when these symptoms present
[4]. These Medicaid/uninsured patients also lack easy access to primary
care for early detection and appropriate referral [4]. With the aim to
better understand the association between insurance status and cancer
care outcomes, the current study demonstrates that managed care in
surance is associated with improved overall survival. Furthermore, this
study reveals that, outside of comparison with Medicaid or uninsured
patients, there were no significant differences between Medicare and
other managed care insurance products.
The current study further demonstrates that even after controlling
for geocoded patient socioeconomic markers, insurance status continues
to be associated with overall survival. The higher overall survival seen in
the FFS group may be attributed to the younger mean age of this pop
ulation. The early presentation seen in patients with managed care

Fig. 1. Overall log-rank p-value for equality over strata is statistically signifi
cant at <0.001. Abbreviations: HFMG, Henry Ford Medical Group.

Table 6
Multivariable survival model of insurance type when controlling for socioeconomic variables.
Variable

Response

Deaths (N)

Median survival time (months), 95% CI

HR

Insurance group

HMO
FFS
HFMG
Medicaid
Uninsured
$2499 - $23,385
$23,438 - $35,170
$35,250 - $47,574
$47,833 - $62,898
$62,969 - $187,639
Own
Rent
Every 1% increase
<High school
High school
Bachelor
Post grad
Some college
Every 1-year increase
Male
Female
White
Black
Other
0
I, IA, IB
II
III
IV
IVA
IVB/IVC

52
197
46
12
46
76
70
71
68
50
237
88

116.1 (84.3, 167.1)
81.8 (66.4, 93.1)
133.9 (97.0, 178.2)
135.1 (28.1, N/A)
29.8 (20.3, 44.8)
44.1 (34.2, 62.4)
80.9 (45.8, 100.7)
97.5 (66.6, 120.4)
84.3 (56.0, 124.7)
133.9 (107.5, 211.2)
100.4 (86.2, 111.7)
42.5 (30.9, 63.3)

31
140
14
1
145

46.3 (20.3, 80.7)
77.5 (52.7, 90.4)
107.5 (31.2, N/A)
N/A (72.4, N/A)
100.4 (86.3, 120.6)

76
277
204
146
1
21
95
65
49
41
69
13

93.1 (80.4, 106.2)
64.4 (43.5, 97.5)
97.5 (81.8, 111.3)
66.6 (48.3, 88.0)
N/A (15.1, N/A)
N/A (111.7, N/A)
120.6 (102.1, 150.9)
91.3 (64.4, 114.7)
69.0 (35.2, 87.6)
40.3 (18.6, 58.8)
29.3 (17.8, 52.2)
4.8 (1.5, 11.0)

(ref)
0.78
0.57
0.88
1.85
1.28
1.15
1.19
1.04
(ref)
(ref)
0.91
1.61
1.05
1.03
1.14
0.25
(ref)
1.06
(ref)
1.34
(ref)
0.79
0.33
(ref)
1.56
2.35
3.11
3.63
5.16
28.56

Median household income

Housing
Houses in poverty (%)
Education

Age
Sex
Race
AJCC stage

95% CI
0.55, 1.11
0.37, 0.88
0.43, 1.80
1.16, 2.93
0.74, 2.20
0.72, 1.83
0.78, 1.81
0.70, 1.54
0.68, 1.21
0.52, 4.98
0.66, 1.68
0.80, 1.34
0.64, 2.03
0.04, 1.85
1.05, 1.08
1.01, 1.76
0.59, 1.05
0.04, 2.44
0.94, 2.59
1.38, 3.98
1.78, 5.46
2.03, 6.49
3.00, 8.86
12.81, 63.7

4
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The limitations of the current study include the inherent variability
within each insurance type and lack of individualized data regarding
SES with respect to patient-specific socioeconomic variables. Not all
policies within an insurance type offer the same coverage, copays, or
deductible, thus access to care can vary widely within any one insurance
type. We used census-block level data as proxy for individual level
markers of SES. Thus, the SES markers presented in this paper are
population level variables for the patient census block, not individual
variables. This points to a need for additional research examining in
dividual patient-level socioeconomic variables and the systematic
gathering of this data in an electronic medical record. Additional inquiry
could also be made with respect to other individual factors that have
been shown to influence survival, such as social support, marital status,
comorbidity, and health behaviors (i.e., tobacco and alcohol use). These
factors, along with insurance type, may prompt patients experiencing
symptoms of possible laryngeal cancer to seek treatment earlier rather
than later, as well as influencing adherence to treatment and surveil
lance, and thus, affecting survival probabilities.

uninsured [7]. Ellis et al. demonstrated that for certain types of cancers
there was no difference in survival between private insurance, Medicaid,
and Medicare, specifically for prostate and lung cancer patients; how
ever, for other types of cancers, such as breast, colorectal and melanoma,
survival in the private insurance group was much better than Medicaid,
Medicare and the uninsured [7]. The associations between cancerspecific survival and insurance status may be explained by cancerspecific biology and the cancer care pathway currently recommended
for each type of cancer. This may apply to laryngeal cancer as well; the
common symptoms of laryngeal cancer likely prompt patients to seek
evaluation by their primary care provider, if they have access, and thus
are more likely to receive timely referral to an otolaryngologist for
diagnosis. It is interesting that HFMG patients had an older mean age
and lower median income, yet they were comparable in survival with
the younger FFS patients. The improved survival seen in patients with
private insurance may also be secondary to their financial advantage as
demonstrated in the analysis of SES markers and survival
[4,6–10,12,13].
Whether managed care/HMOs provide better coordination of care
compared to private insurances, such as the FFS model, is a point of
contention [14]. Managed care in the setting of oncological care has
been an area of intense debate and is highlighted in an editorial in 2000
published in the Journal of Clinical Oncology [14]. The editorial stated
that managed care, although providing excellent preventative care,
falters in providing long-term cancer care and care to the elderly with
multiple comorbidities. This is somewhat intuitive as preventative care
is geared towards younger patients. This piece also highlighted that the
poor and the elderly have worse outcomes in cancer care under managed
care compared to FFS care [14]. There was also a call for improvement
in coordination for patients with cancer under managed care since many
patients with cancer experience delays in proper referral to cancer
specialists and access to quality clinical trials. Other research has
highlighted the strength of managed care in the ambulatory setting and
in preventative care [15,16]. Ayanian et al. did distinguish that although
HMOs collectively had a poor performance record even compared to
traditional Medicare in the early 2000s, HMOs have since caught up to
and even surpassed Medicare on several quality metrics. However, this
has only been noted for care in the ambulatory setting. In some ambu
latory settings, HMOs provide equal if not better quality of care than the
FFS model [16]. It is important to note that not all HMOs are made the
same [15]. Larger, more established HMOs have demonstrated robust
improvements over time, but smaller and newer ones appear to struggle
[15]. Although there is no direct reference to cancer care for the latter
two studies, these studies suggest that HMOs have demonstrated
improvement in coordination of care over time, and certain factors make
some HMOs more reliable in providing better care than others. This is
also reflected in the current study where the HFMG cancer patients
demonstrated comparable survival despite the older mean age compared
to the FFS group. These results may reflect the improving trend in co
ordination of cancer care under HMOs/managed care.
HPV status has significant influence on overall survival and disease
progression in patients with oropharyngeal squamous cell carcinoma
[17]. This finding however is not supported in patients with laryngeal
squamous cell carcinoma, as disease-specific survival is most impacted
by nicotine exposure and tumor staging in laryngeal cancer [21]. Fakhry
et al. describes a large institutional study including 140 laryngeal cancer
specimens, of which 7 cases (5%) were found to be HPV-positive with no
prognostic difference when compared to patients with HPV-negative
laryngeal cancer [19]. In this study, HPV testing was not done on the
majority of laryngeal cancer specimens in our patient cohort because of
the unproven prognostic significance, so this study does not include a
sub-analysis between HPV status, insurance status, and overall survival
[18–20]. However, the role of HPV status, though strong in oropha
ryngeal cancers, should be further studied in patients with laryngeal
cancer in addition to investigating interactions between insurance and
SES with subsequent studies.

5. Conclusion
Contemporary head and neck cancer care is multidisciplinary and
requires a significant amount of coordination to provide quality treat
ment. This study explores the outcome in overall survival with respect to
the type of insurance. It also examines the influence of SES for each
insurance type and overall survival. The type of insurance or lack of
insurance is significantly associated with stage at presentation and
survival/treatment outcomes. In this study, HMO and HFMG demon
strated improved overall survival compared to a Medicaid or uninsured
group. The FFS group had a higher median survival overall; however,
despite differences in mean age and income, HFMG had a similar sur
vival median. These findings may reflect the closing gap in disparities
between HMOs and FFS, although further research is needed to explore
this topic. This study also lends information for patients and consumers
regarding the changing mandate on health insurance. With the intro
duction and subsequent changes with the Affordable Care Act and
resultant insurance marketplaces, different insurance plans are being
purchased with decision falling on the individual to determine the type
of insurance. Future research should explore different treatment times of
patients diagnosed with laryngeal cancer, how it differs with respect to
insurance type and how this can influence overall survival. Additional
psychosocial variables affecting cancer care and coordination should
also be examined, such as social support, individual SES, and education.
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